Insulet Corporation(PODD)- NASDAQ
  • Tue, Sep. 13, 7:13 AM
    • The first patient completes Insulet's (NASDAQ:PODD) feasibility study evaluating the use of a personal Model Predictive Control algorithm with its Omnipod Horizon Automated Glucose Control System. 20 patients will participate in the study, the aim of which is gather data in order to fine-tune the algorithm for further studies leading to a regulatory application in the U.S.
    • Omnipod Horizon is an integrated system comprised of an on-body Omnipod tubeless pump, the latest Dexcom (NASDAQ:DXCM) continuous glucose monitoring technology, a modified version of Insulet's handheld controller and state-of-the-art security system architecture. The algorithm projects the future horizon of blood glucose levels and adjusts insulin delivery to an optimal level for each user. It can provide three days of non-stop insulin delivery without the need to disconnect a tube set or manually inject insulin.
    | Tue, Sep. 13, 7:13 AM
  • Thu, Sep. 8, 7:16 AM
    • Insulet (NASDAQ:PODD) sets the terms of its private placement of $300M (up from $250M) principal amount of convertible senior notes due September 15, 2021 unless earlier converted, purchased or redeemed. The Notes will bear an annual interest rate of 1.25%. Initial buyers will have an option to purchase up to an additional $45M of the Notes.
    • The Notes will be convertible on the business day preceding June 15, 2021 only under certain circumstances and freely convertible thereafter. The initial conversion rate is 17.1332 shares of common stock per $1,000 principal amount of the Notes ($58.37 per share). At the company's election, the Notes can be settled in cash, shares or a combination thereof.
    • Net proceeds should be ~$290M. Insulet will use ~$154M to repurchase ~$134M principal amount of its outstanding 2.00% convertible senior notes due 2019. The remainder will be used for general corporate purposes.
    | Thu, Sep. 8, 7:16 AM
  • Tue, Sep. 6, 5:41 PM
    • Insulet (NASDAQ:PODD) announces its plan to offer $250M aggregate principal amount of convertible senior notes due 2021 in a private placement. Initial buyers will have to option to purchase up to an additional $37.5M of the notes. Price, yield and conversion price have not been released.
    • Net proceeds will be used for general corporate purposes.
    | Tue, Sep. 6, 5:41 PM
  • Thu, Aug. 4, 12:55 PM
    | Thu, Aug. 4, 12:55 PM | 1 Comment
  • Thu, Aug. 4, 11:00 AM
    | Thu, Aug. 4, 11:00 AM | 1 Comment
  • Wed, Aug. 3, 5:35 PM
    | Wed, Aug. 3, 5:35 PM
  • Wed, Aug. 3, 4:25 PM
    • Insulet (NASDAQ:PODD): Q2 EPS of -$0.08 beats by $0.09.
    • Revenue of $87.33M (+44.2% Y/Y) beats by $6.14M.
    • Press Release
    | Wed, Aug. 3, 4:25 PM
  • Tue, Aug. 2, 5:35 PM
  • Wed, May 4, 6:50 AM
    • Insulet (NASDAQ:PODD) reaffirms its revenue guidance for 2016 of $330M - 350M, up 25 - 33% yoy. For Q2, it expects the top line to come in at $81M - 84M, up 34 - 39% yoy.
    | Wed, May 4, 6:50 AM
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Thu, Apr. 28, 4:26 PM
    • Insulet (NASDAQ:PODD): Q1 EPS of -$0.19 in-line.
    • Revenue of $81.2M (+32.6% Y/Y) beats by $2.04M.
    • Shares +1.2%.
    • Press Release
    | Thu, Apr. 28, 4:26 PM | 5 Comments
  • Wed, Apr. 27, 5:35 PM
  • Fri, Feb. 26, 3:58 PM
    • Achillion Pharmaceuticals (ACHN +7.4%) upgraded to Outperform from Neutral with a $10 (36% upside) price target by Baird
    • Insulet (PODD +8.5%) upgraded to Buy from Hold with a $40 (25% upside) price target by Benchmark.
    • DENTSPLY (XRAY -0.1%) upgraded to Neutral from Sell by UBS. Price target raised to $60 (1% downside risk) from $50.
    • PTC Therapeutics (PTCT -29.4%) upgraded Hold from Underperform by Jefferies. Price target lowered to $12 (22% upside) from $18.
    • AbbVie (ABBV -0.3%) upgraded to Buy from Neutral by Citigroup. Price target raised to $65 (16% upside) from $56.
    • Wellcare Health Plans (WCG +0.7%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $114 (24% upside) from $80.
    • Keryx Biopharmaceuticals (KERX +8.7%) downgraded to Neutral from Overweight by JP Morgan.
    • Peregrine Pharmaceuticals (PPHM -62.1%) downgraded to Neutral from Buy with a $0.50 (25% upside) price target by Roth Capital.
    • EXACT Sciences (EXAS -1.8%) downgraded to Neutral from Buy by Roth Capital and Equal Weight from Overweight by Stephens & Co.
    • Radius Health (RDUS -2.8%) downgraded to Hold from Buy with a $37 (23% upside) price target by Jefferies.
    • PTC Therapeutics (PTCT -29.4%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $13 (56% upside) from $90.
    • Orexigen (OREX -31.9%) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $2 (104% upside) from $4.50.
    • Express Scripts (ESRX +2.4%) downgraded to Sell from Hold by Deutsche Bank. Price target lowered to $61(15% downside risk) from $93.
    • Perrigo (PRGO) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $124 (4% downside risk) from $160.
    • Chimerix (CMRX -6.6%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $9 (91% upside) from $13.
    | Fri, Feb. 26, 3:58 PM | 8 Comments
  • Fri, Feb. 26, 1:53 PM
    • GlaxoSmithKline (GSK -0.9%) initiated with Hold rating and 1400p price target (-0.7% downside risk) by Cantor Fitzgerald.
    • Shire plc (SHPG -0.6%) initiated with Buy rating by Cantor Fitzgerald.
    • Insulet (PODD +8.7%) initiated with Sell rating and $15 (53% downside risk) price target by Empire Asset Management.
    • MacroGenics (MGNX +2.2%) initiated with Equal Weight rating and $20 (29% upside) price target by Morgan Stanley.
    • Biogen (BIIB +0.8%) initiated with Buy rating and $345 (30% upside) price target by Citigroup.
    • Boston Scientific (BSX -0.3%) initiated with Buy rating and $21 (22% upside) price target by SunTrust Robinson Humphrey.
    • Other initiations by Citigroup: Amgen (AMGN +1.1%) Neutral rating and $165 (11% upside) price target; Celgene (CELG +1.4%) Buy rating and $130 (25% upside) price target; Regeneron Pharmaceuticals (REGN) Buy rating and $480 (22% upside) price target; Alexion Pharmaceuticals (ALXN +0.1%) Neutral rating and $165 (18% upside) price target.
    • IMS Health Holdings (IMS +0.2%) initiated with Outperform rating and $31 (19% upside) price target by Leerink Swann.
    • Ocera Therapeutics (OCRX +5.7%) initiated with Buy rating and $10 (229% upside) price target by Brean Capital.
    • Repligen (RGEN +3.8%) initiated with Buy rating and $36 (35% upside) price target by Craig-Hallum.
    • Mesoblast (MESO -2.2%) initiated with Neutral rating and $5.50 (12% downside risk) price target by Chardan Capital.
    • Ultragenyx Pharmaceutical (RARE +1.2%) initiated with Buy rating and $80 (29% upside) price target by Leerink Swann.
    • Teva Pharmaceutical Industries (TEVA -0.2%) initiated with Outperform rating with $68-71 (21% upside from midpoint) price target by Wells Fargo.
    • Medivation (MDVN +9.8%) initiated with Buy rating and $46 (28% upside) price target by Bank of America.
    • Collegium Pharmaceutical (COLL -0.1%) initiated with Outperform rating and $35 (83% upside) price target by William Blair.
    | Fri, Feb. 26, 1:53 PM | 5 Comments
  • Thu, Feb. 25, 4:26 PM
    • Insulet (NASDAQ:PODD) Q4 results ($M): Revenues: 100.1 (+37.9%); Operating Expenses: 69.4 (+78.4%); Net Loss: (27.3) (-405.6%); Loss Per Share: (0.48) (-380.0%).
    • 2016 Guidance: Revenues: $330M - 350M.
    • Q1 Guidance: Revenues: $77M - 80M.
    • Shares are up 3% after hours on light volume.
    | Thu, Feb. 25, 4:26 PM
  • Thu, Feb. 25, 4:06 PM
    • Insulet (NASDAQ:PODD): Q4 EPS of -$0.48 may not be comparable to consensus of -$0.26.
    • Revenue of $100.1M (+38.0% Y/Y) beats by $8.21M.
    • Shares -1%.
    | Thu, Feb. 25, 4:06 PM